MA56391B1 - GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS - Google Patents

GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS

Info

Publication number
MA56391B1
MA56391B1 MA56391A MA56391A MA56391B1 MA 56391 B1 MA56391 B1 MA 56391B1 MA 56391 A MA56391 A MA 56391A MA 56391 A MA56391 A MA 56391A MA 56391 B1 MA56391 B1 MA 56391B1
Authority
MA
Morocco
Prior art keywords
glucagon
peptide
receptor agonists
compound
formula
Prior art date
Application number
MA56391A
Other languages
French (fr)
Other versions
MA56391A (en
Inventor
Fucheng Qu
David Andrew Coates
Todd Fields
Joseph Daniel Ho
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from PCT/US2020/038617 external-priority patent/WO2020263695A1/en
Publication of MA56391A publication Critical patent/MA56391A/en
Publication of MA56391B1 publication Critical patent/MA56391B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dans un mode de réalisation, la présente invention concerne un composé de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci, et des procédés d'utilisation de ce composé pour le traitement du diabète sucré de type ii.In one embodiment, the present invention relates to a compound of formula (i) or a pharmaceutically acceptable salt thereof, and methods of using the compound for the treatment of type ii diabetes mellitus.

MA56391A 2019-06-28 2020-06-19 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS MA56391B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962868117P 2019-06-28 2019-06-28
PCT/US2020/038617 WO2020263695A1 (en) 2019-06-28 2020-06-19 Glucagon-like peptide 1 receptor agonists

Publications (2)

Publication Number Publication Date
MA56391A MA56391A (en) 2022-05-04
MA56391B1 true MA56391B1 (en) 2023-11-30

Family

ID=80781601

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56391A MA56391B1 (en) 2019-06-28 2020-06-19 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS

Country Status (2)

Country Link
AR (1) AR119173A1 (en)
MA (1) MA56391B1 (en)

Also Published As

Publication number Publication date
AR119173A1 (en) 2021-12-01
MA56391A (en) 2022-05-04

Similar Documents

Publication Publication Date Title
SA521431209B1 (en) Glucagon-like Peptide 1 Receptor Agonists
HRP20191614T1 (en) Gip and glp-1 co-agonist compounds
MX2023001311A (en) Heterocyclic glp-1 agonists.
MA48051B1 (en) A sodium salt of n - ((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl) carbamoyl) -1-isopropyl-1h-pyrazole-3-sulfonamide
MX2022009524A (en) Heterocyclic glp-1 agonists.
CR20220020A (en) Gipr-agonist compounds
MA37866B1 (en) Aza-indazole or diaza-indazole derivatives for the treatment of pain
TN2009000204A1 (en) SPIROCETONES AS INHIBITORS OF ACETYL-COA-CARBOXYLASE
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
CO5150222A1 (en) METHOD AND COMBINATION USING (-) NORCISAPRIDA IN COMBINATION WITH PROTON PUMP INHIBITORS OR RECEIVER ANTAGONISTS H [sub 2]
CL2011001848A1 (en) Compounds derived from pyrimidine fused to a 5-membered heterocycle; angiotensin ii receptor antagonist, peroxisome proliferator receptor agonist; pharmaceutical composition; and use of the compounds in the treatment of circulatory diseases such as hypertension, heart disease, arteriosclerosis, among others.
AR045173A1 (en) COMPOUNDS THAT HAVE INHIBITORY ACTIVITY AGAINST TRANSPORTER OF GLUCOSE DEPENDENT ON SODIUM
MA34885B1 (en) GLUCAGON ANALOGS HAVING A GIP RECEPTOR ACTIVITY
DK1888103T3 (en) USE OF GLP-1, EXENDIN AND AGONISTS THEREOF TO DELAY OR PREVENT CARDIAL REMODELING
MA27498A1 (en) PHARMACEUTICAL COMPOSITIONS OF SERTACONAZOLE FOR VAGINAL USE.
MA38534A1 (en) Synergistic compositions including (2s) -2-ethoxy-3- (4- (2- (2-methyl-5- (4-methylsulfanylphenyl) pyrrol-1-yl) ethoxy) phenyl) propanoate and agents, e.g. Dipeptidyl peptidase-4, biguanide and / or statin inhibitors for use in dyslipidemia
MA38078B1 (en) Pyridine derivative
JP2023156353A (en) Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (rage)
MA58993A1 (en) CRF1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA
Santin et al. Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions
MA53711A (en) ALPHA 2-ADRENERGIC SUBTYPE C (ALPHA-2C) RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA
MA56391B1 (en) GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS
MX2023013717A (en) Macrocyclic glucagon-like peptide 1 receptor agonists.
MA30523B1 (en) TRICYL COMPOUND AND PHARMACEUTICAL USE OF IT
EA202190398A1 (en) CONDENSED RING DERIVATIVE USED AS FGFR4 INHIBITOR